Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Abatacept pilot trial in a child with IPEX syndrome
2008-003368-21Phase 3Completed
- Sponsor
- IRCCS Burlo Garofolo
- Start
- Feb 2009
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of abatacept in Immunodysregulation Polyendocrinopathy Enteropathy X-Linked Syndrome (IPEX), sponsored by IRCCS Burlo Garofolo. Primary endpoints: Survival without new autoimmune phenomena, Autoimmune flares and 1 more. Started Feb 2009; status: completed.
02
Drugs
abatacept
03
Conditions
Immunodysregulation Polyendocrinopathy Enteropathy X-Linked Syndrome (IPEX)
Beyond the preview
Go deeper on 2008-003368-21.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-003368-21.